Heart failure: LCZ696, an angiotensin-neprilysin inhibitor, superior to Enalapril in reducing the risks of death and of hospitalization
Researchers have compared the angiotensin receptor-neprilysin inhibitor LCZ696 with Enalapril in patients who had heart failure with a reduced ejection fraction.
In previous studies, Enalapril improved survival in such patients.
In this double-blind trial, PARADIGM-HF, 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less were randomly assigned to receive either LCZ696 ( at a dose of 200 mg twice daily ) or Enalapril ( at a dose of 10 mg twice daily ), in addition to recommended therapy.
The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.
The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed.
At the time of study closure, the primary outcome had occurred in 914 patients ( 21.8% ) in the LCZ696 group and 1117 patients ( 26.5% ) in the Enalapril group ( hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P less than 0.001 ).
A total of 711 patients ( 17.0% ) receiving LCZ696 and 835 patients ( 19.8% ) receiving Enalapril died ( hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P less than 0.001 ); of these patients, 558 ( 13.3% ) and 693 ( 16.5% ), respectively, died from cardiovascular causes ( hazard ratio, HR=0.80; 95% CI, 0.71 to 0.89; P less than 0.001 ).
As compared with Enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% ( P less than 0.001 ) and decreased the symptoms and physical limitations of heart failure ( P = 0.001 ).
The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the Enalapril group.
In conclusion, LCZ696 was superior to Enalapril in reducing the risks of death and of hospitalization for heart failure.
McMurray JJV et al, N Engl J Med 2014; 371:993-1004